Lupin to Present Phase 1a Data on STING Agonist LNP3693 at ESMO 2025
Key Insights
Lupin will present Phase 1a clinical trial data for LNP3693, an investigational STING (search) agonist, at the ESMO Congress 2025 in Berlin from October 17-21, 2025.
The presentation will provide insights into LNP3693's safety profile, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with advanced solid tumors (search) and lymphoma (search).
This milestone follows Lupin's successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, highlighting the company's progress in oncology drug discovery.
Global pharmaceutical company Lupin Limited will present Phase 1a clinical trial data for its investigational STING (search) agonist LNP3693 at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, from October 17 to October 21, 2025. The presentation will focus on the drug's safety profile, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with advanced or metastatic solid tumors (search) and lymphoma (search).
Clinical Trial Details
The presentation, titled "A phase 1 dose escalation study of LNP3693 (STING (search) agonist) in patients with advanced or metastatic solid tumors (search) & lymphoma (search)," will be featured in the Investigational Immunotherapy session with presentation number 1553P. The data will be available for viewing on October 19, 2025, from 09:00 to 17:00 CEST.
LNP3693 is an investigational parenteral STING (search) (Stimulator of Interferon Genes) agonist currently being evaluated in a Phase 1a dose escalation study. The clinical trial is registered under CTRI/2023/10/059147 and assessed how the drug behaves in the body, its safety across different doses, and its ability to target and reduce tumor growth.
Company Leadership Perspective
"This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING (search) agonist, at ESMO," said Vinita Gupta, CEO of Lupin. "ESMO's acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development."
Research Significance
The presentation will provide qualitative insights into LNP3693's therapeutic potential as a cancer treatment option. The trial evaluated the drug's pharmacokinetic properties, safety profile across different dosing levels, and its preliminary effectiveness in targeting tumor growth in patients with solid tumors (search) and lymphoma (search).
Lupin's participation at ESMO 2025 represents the company's ongoing commitment to oncology research and development, building on their previous success with LNP7457 presented at the American Society of Clinical Oncology (ASCO) meeting in June 2025.
Publication and Access
All regular abstracts accepted for presentation at the ESMO Congress 2025 were published online via the ESMO website on Monday, October 13, at 6:05 p.m. ET (12:05 a.m. CEST). The accepted abstracts are also available in the ESMO Congress 2025 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.